Brokerages forecast that Syndax Pharmaceuticals Inc (NASDAQ:SNDX) will post $380,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Syndax Pharmaceuticals’ earnings. Syndax Pharmaceuticals posted sales of $1.19 million in the same quarter last year, which suggests a negative year over year growth rate of 68.1%. The business is scheduled to issue its next earnings report on Monday, March 4th.
On average, analysts expect that Syndax Pharmaceuticals will report full-year sales of $1.66 million for the current year, with estimates ranging from $1.50 million to $2.11 million. For the next year, analysts forecast that the business will report sales of $1.63 million, with estimates ranging from $1.40 million to $2.11 million. Zacks’ sales calculations are an average based on a survey of analysts that cover Syndax Pharmaceuticals.
Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Monday, November 5th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 91.11% and a negative net margin of 3,185.75%.
Institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company increased its holdings in shares of Syndax Pharmaceuticals by 266.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 10,566 shares of the company’s stock worth $151,000 after buying an additional 7,686 shares during the last quarter. Rhumbline Advisers acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at approximately $103,000. DRW Securities LLC acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at approximately $105,000. Claraphi Advisory Network LLC acquired a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at approximately $129,000. Finally, Bank of America Corp DE increased its holdings in Syndax Pharmaceuticals by 1,382.0% in the 2nd quarter. Bank of America Corp DE now owns 28,084 shares of the company’s stock valued at $197,000 after purchasing an additional 26,189 shares during the last quarter. Institutional investors own 64.38% of the company’s stock.
Shares of NASDAQ SNDX traded down $0.03 during trading hours on Tuesday, reaching $5.44. The stock had a trading volume of 1,300 shares, compared to its average volume of 422,670. The firm has a market capitalization of $129.89 million, a price-to-earnings ratio of -1.88 and a beta of 2.63. Syndax Pharmaceuticals has a 52-week low of $4.36 and a 52-week high of $15.20.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Recommended Story: Initial Public Offering (IPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.